Abstract | BACKGROUND: DESIGN: Interventional comparative study. PARTICIPANTS: The study included patients undergoing an intravitreal ranibizumab injection about one week before anti-glaucomatous surgery (study group) or who underwent routine cataract surgery (control group). METHODS: MAIN OUTCOME MEASURES: Concentrations of PEDF and VEGF-A in aqueous. RESULTS: At baseline, concentrations VEGF-A (3698 ± 2105 pg/mL vs. 233 ± 98 pg/mL) and PEDF (18.9 ± 11.9 ug/mL vs. 2.2 ± 0.6 ug/mL) were higher (P < 0.001) in the study group (n = 20 patients) than control group (n = 20 patients). The VEGF-A/PEDF concentration ratio was higher in the study group (396 ± 554 vs. 110 ± 49; P = 0.02). One week after the ranibizumab injection, iris neovascularization had completely regressed in 17 (85%) eyes, and VEGF-A concentration decreased significantly (P < 0.001) to 184 ± 130 pg/mL. The PEDF concentration remained unchanged (19 ± 12 ug/mL). The VEGF-A/PEDF concentration ratio decreased to 13.2 ± 13.6. Plasma concentrations of VEGF-A and PEDF did not differ significantly between both groups (P = 0.65 and P = 0.15, respectively) nor were they significantly correlated with the aqueous concentrations (all P > 0.15). CONCLUSIONS:
|
Authors | Jia Wei Wang, Min Wen Zhou, Xiulan Zhang, Wen Bin Huang, Xin Bo Gao, Wei Wang, Shida Chen, Xin Yu Zhang, Xiao Yan Ding, Jost B Jonas |
Journal | Clinical & experimental ophthalmology
(Clin Exp Ophthalmol)
Vol. 43
Issue 5
Pg. 415-21
(Jul 2015)
ISSN: 1442-9071 [Electronic] Australia |
PMID | 25488632
(Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | © 2014 Royal Australian and New Zealand College of Ophthalmologists. |
Chemical References |
- Angiogenesis Inhibitors
- Eye Proteins
- Nerve Growth Factors
- Serpins
- VEGFA protein, human
- Vascular Endothelial Growth Factor A
- pigment epithelium-derived factor
- Ranibizumab
|
Topics |
- Adult
- Aged
- Angiogenesis Inhibitors
(therapeutic use)
- Aqueous Humor
(metabolism)
- Enzyme-Linked Immunosorbent Assay
- Eye Proteins
(metabolism)
- Female
- Fluorescein Angiography
- Glaucoma, Neovascular
(drug therapy, metabolism)
- Humans
- Intravitreal Injections
- Male
- Middle Aged
- Nerve Growth Factors
(metabolism)
- Prospective Studies
- Ranibizumab
(therapeutic use)
- Serpins
(metabolism)
- Vascular Endothelial Growth Factor A
(antagonists & inhibitors, metabolism)
- Visual Acuity
|